CA-ENLIGHTED
16.7.2020 12:02:06 CEST | Business Wire | Press release
Enlighted , the leading building IoT platform provider, expands its award-winning IoT technology with workplace digital contact tracing to help employees return safely to manufacturing facilities, pharmaceutical labs, offices and more. Safe provides digital contact history for employees who self-report testing positive for COVID-19 to help reduce the spread of infection, keep healthy employees safe and productive, and eliminate the tedious, expensive and error-prone manual contact tracing process for employers.
The solution prioritizes data privacy without the need for storing personal information. Employees are assigned alphanumeric ID badges while entering the workplace. When an employee self-reports their badge ID and a positive test result, administrators query the Safe application, identify other IDs this badge came in contact with and share the anonymous IDs. Employees carrying those badge IDs can self-identify their exposure.
The Enlighted solution provides employers with location and proximity data to identify who an infected employee came in contact with inside the workplace, for how long and what areas they visited. The data is used to inform employees who might be at risk of infection and also drives sanitization efforts in areas the infected employee utilized. The application’s dashboard provides information on contacts in the building to assist management in developing safer workplace strategies. Additionally, Safe identifies how many close contacts are happening in a time period and location to proactively manage risk.
Enlighted is in a unique position to provide proven safer workplace solutions for COVID-19 and beyond with its IoT technology already installed in 320 million square feet of buildings globally. Existing customers can simply add the Safe app to their IoT platform. New customers can install the Enlighted IoT system through sensors in LED lighting or through the new USB-powered surface sensor , which can be easily applied under desks or in conference rooms.
“The important role of IoT technology in buildings has been further magnified by the COVID-19 pandemic,” said Stefan Schwab, CEO of Enlighted, a Siemens company. “The Enlighted sensory system can now provide digital contact tracing. It also lays the foundation for future-proofed buildings ready to help us understand with real-time data the changing nature of our at-work experiences and meet challenges beyond COVID-19.”
Enlighted offers a suite of data-driven safer workplace solutions , assisting planners in preparing and executing physical distancing processes, enhanced sanitization and monitoring, occupancy limits and now contact tracing. The IoT platform also integrates through APIs with third-party systems to provide touchless entry, smart desk hoteling, conference room booking and more.
The Safe application is available immediately for new and existing Enlighted customers. Visit www.enlightedinc.com/contact-sales to talk with a sales representative or request a demonstration, or visit http://www.enlightedinc.com to learn about Enlighted’s full suite of workplace safety solutions.
ABOUT ENLIGHTED
Designed to change everything, Enlighted provides the world’s most advanced Building IoT Platform for leading commercial and healthcare organizations around the globe, with more than 320 million square feet of building space deployed to date. Founded in 2009 and headquartered in Silicon Valley, Enlighted was acquired in 2018 and is a wholly-owned subsidiary of Siemens Industry, Inc. as part of Siemens Smart Infrastructure. For more information about Enlighted, visit enlightedinc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005237/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
Andersen Consulting får ny samarbejdspartner i Usbekistan22.10.2026 21:34:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for cybersikkerhed og forretningstransformation gennem en samarbejdsaftale med Algoruni, et konsulentfirma med base i Usbekistan. Algoruni rådgiver organisationer om at opbygge cyberrobusthed og håndtere bredere prioriteter inden for ledelse, regulering og bæredygtighed. Virksomheden har base i Tasjkent og tilbyder tjenester inden for cybersikkerhedsstrategi og databeskyttelse, virksomhedsledelse og driftsforbedringer samt ESG-strategi og -rapportering. Fokus er på praktiske løsninger, der er tilpasset den enkelte kundes situation. "Enhver organisation står over for en unik kombination af risici og muligheder. Derfor mener vi, at effektive løsninger skal tage udgangspunkt i virksomhedens konkrete situation," udtalte Alisher Zaynutdinov, administrerende direktør for Algoruni. "Som samarbejdsvirksomhed med Andersen Consulting kan vi kombinere denne tilgang med et bredere netværk af internationale ressourcer og perspektiver, så vi får nye
Andersen Global udvider sine juridiske kompetencer i Argentina gennem samarbejde med MHR22.10.2026 20:20:00 CEST | Pressemeddelelse
Andersen Global styrker sine juridiske kompetencer i Argentina gennem en samarbejdsaftale med Martínez de Hoz & Rueda (MHR) efter integrationen af teamet fra MBP Partners i firmaet. MBP Partners var tidligere et samarbejdsfirma i Andersen Global og arbejdede sammen med organisationens medlemsfirmaer og samarbejdsfirmaer for at bistå klienter med både lokale og internationale forhold. Med integrationen af MBP Partners viderefører den nye samarbejdsaftale mellem Andersen Global og MHR det eksisterende samarbejde og styrker samtidig Andersen Globals juridiske kompetencer i Argentina. MHR er et fullservice advokatfirma, der rådgiver klienter inden for olie og gas, selskabsretlige og finansielle forhold, energi, minedrift, fintech, infrastruktur, teknologi og andre centrale sektorer. Firmaet bistår danske og internationale virksomheder, finansielle institutioner, investeringsfonde, fintechvirksomheder og andre organisationer med komplekse transaktioner, regulatoriske spørgsmål og strategisk
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press release
For Trade and Medical Media Only Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoi
Tigo Energy Improves Installer Choice via Fronius Compatibility with TS4 Product Line22.10.2026 18:02:00 CEST | Press release
Compatibility between Tigo MLPE and multiple Fronius inverter families gives solar installers worldwide greater flexibility to design high-quality systems with the features customers want. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a manufacturer declaration of compatibility from Fronius International GmbH, documenting compatibility between Tigo Flex MLPE products and multiple Fronius inverter families. The letter covers Tigo TS4-A-F, TS4-A-2F, TS4-A-O, and TS4-X-O products and the Fronius Primo GEN24, Primo GEN24 208-240, Symo GEN24, Verto, Tauro, and Tauro ECO inverter families, when configured according to the requirements specified by Fronius and Tigo. Building on established compatibility in Europe, the declaration extends manufacturer-confirmed compatibility to markets worldwide, including the United States and Canada, giving solar professionals greater flexibility to design high-q
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
